Apollo Hospitals Hits All-Time High: What Drove the Rally?

Rahul Asati Image

Rahul Asati

Last updated:
7 min read
image with title "Apollo Hospitals Hits All-Time High  What Drove the Rally?"
Table Of Contents
  • Why Is Apollo Hospitals Share Price Rising?
  • Apollo Hospitals Q2 Results: Profits Growing Faster Than Revenue
  • Apollo Plans to Add 5,800 Beds, But Can It Maintain Profit Margins?
  • Apollo's Pharmacy Business Could Be Another Growth Driver
  • What Are the Risks for Apollo Hospitals Investors?
  • Author's Take

Apollo Hospitals' share price surged over 5% on November 20, 2026, crossing ₹9,200 and reaching a fresh all-time high. The rally came after global brokerage Macquarie upgraded the stock by two levels and raised its target price from ₹6,230 to ₹10,500.

However, the brokerage upgrade is only part of the story. Apollo Hospitals is reporting stronger profits, treating more patients and preparing to add thousands of hospital beds over the coming years. Interestingly, its established hospitals are becoming more profitable even as newer hospitals continue to report losses.

So, what changed in the outlook for Apollo Hospitals? And can the company's growing hospital network support its rising share price? Let's understand the factors behind the rally and what investors should watch next.

Why Is Apollo Hospitals Share Price Rising?

The immediate trigger behind Apollo Hospitals' rally was a double upgrade by global brokerage Macquarie. The brokerage changed its rating from Underperform to Outperform and increased its target price by nearly 69%, from ₹6,230 to ₹10,500.

Macquarie believes that earnings expectations for hospital companies may have bottomed out and that concerns about the cost of expanding hospital capacity are already reflected in market valuations.

Opening a new hospital involves significant upfront expenses. Companies must invest in infrastructure, medical equipment, doctors and staff before the hospital starts attracting enough patients to become profitable. Consequently, aggressive expansion can temporarily reduce profit margins.

However, Macquarie believes new hospital capacity is filling up at a healthy pace, improving the earnings outlook for companies like Apollo Hospitals.

The positive sentiment extended beyond Apollo. Max Healthcare shares also jumped over 4% following a similar upgrade by Macquarie, suggesting that the rally reflected improving investor confidence in the hospital sector.

Apollo Hospitals Q2 Results: Profits Growing Faster Than Revenue

Apollo Hospitals' recent financial performance offers another explanation for the growing investor interest.

In Q2 FY27, the company reported consolidated revenue of ₹7,615 crore, representing 23% year-on-year growth. However, its EBITDA grew faster at 29%, while consolidated profit after tax increased 32%.

Here's how Apollo Hospitals performed during the quarter.

Financial metricQ2 FY27YoY growth
Consolidated revenue₹7,615 crore23%
Consolidated EBITDA₹1,191 crore29%
Consolidated PAT₹630 crore32%
Healthcare services revenue₹3,900 crore23%
Healthcare services EBITDA₹937 crore20%

The interesting part is that Apollo's profits are growing faster than its revenue. Its consolidated EBITDA margin improved from 14.9% in Q2 FY26 to 15.6% in Q2 FY27.

This indicates that the company is generating more operating profit for every rupee of revenue earned. A key contributor is the improving performance of its existing hospital network.

More Patients and Higher Revenue Per Patient

Apollo's hospital business is benefiting from two factors: higher patient volumes and better revenue generation from its existing facilities.

During Q2 FY27, inpatient volumes increased 14% year-on-year, while overall hospital occupancy improved from 69% to 73%.

At the same time, average revenue per patient increased 8% to ₹1,86,880. Why is this important?

Hospitals have significant fixed expenses, including doctors, medical equipment, infrastructure and maintenance. When more patients use the same hospital facilities, these costs can be spread across a larger revenue base, potentially improving profitability.

Apollo also reported stronger demand for specialised treatments. Revenue from oncology grew 28%, gastroenterology increased 27%, and cardiac and orthopaedic services grew 20%.

International patient services revenue also increased 37% year-on-year, indicating rising demand from patients travelling to India for medical treatment.

Together, higher occupancy, patient volumes and specialised treatments are helping Apollo generate more revenue from its hospital network.

Apollo Plans to Add 5,800 Beds, But Can It Maintain Profit Margins?

One of the biggest factors shaping Apollo Hospitals' future is its capacity expansion plan.

The company plans to add approximately 5,800 beds over the next five years. This would significantly increase its hospital network and allow it to treat more patients.

Apollo is already expanding its presence across several major cities, including Pune, Hyderabad, Delhi, Kolkata and Bengaluru. Its upcoming Gurugram hospital, with approximately 470 beds, is also scheduled for commissioning in Q3 FY27.

However, adding hospital beds does not immediately translate into higher profits.

1. New Hospitals Are Still Reporting Losses

In Q2 FY27, Apollo's established hospitals generated ₹3,765 crore in revenue, representing 19% year-on-year growth.

Its newer hospitals, meanwhile, contributed ₹135 crore in revenue but reported an EBITDA loss of ₹35 crore.

This highlights an important difference between operating an established hospital and opening a new one.

An established hospital generally has an existing patient base, operating infrastructure and experienced medical teams. A new hospital must gradually build its reputation, attract patients and improve occupancy before it can reach profitability.

For investors, the key question is not simply how many beds Apollo adds, but how quickly those additional beds start generating profits.

Apollo had 8,522 operating hospital beds as of September 30, 2026, excluding Apollo Health and Lifestyle and managed beds. Its planned addition of 5,800 beds therefore represents a substantial expansion compared with its existing operating capacity, although not all planned beds will necessarily become operational at the same time.

If new hospitals reach healthy occupancy levels faster than expected, they could contribute meaningfully to future earnings. However, slower patient growth or higher operating costs could put pressure on margins.

Apollo's Pharmacy Business Could Be Another Growth Driver

While Apollo Hospitals is primarily known for its hospital network, its pharmacy and digital healthcare businesses are also becoming important contributors to growth.

Apollo HealthCo operates the company's pharmacy distribution business and digital healthcare platform, Apollo 24/7.

During Q2 FY27, HealthCo reported revenue of ₹3,286 crore, an increase of 23% year-on-year. More importantly, its EBITDA increased 75% to ₹193 crore.

The digital business also reached an important milestone. Apollo 24/7 reported a cash operating profit of approximately ₹1 crore, compared with a loss of ₹39 crore in the same quarter last year.

HealthCo's pharmacy network expanded to 7,662 stores as of September 30, 2026, following the addition of 222 net new stores during the quarter.

These developments suggest that HealthCo is improving its profitability alongside business expansion.

Another potential catalyst is Apollo's proposed restructuring and separate listing of its pharmacy and digital healthcare business.

A separate listing could allow investors to assess the value of the hospital operations and the pharmacy business independently. However, the actual impact on shareholder value will depend on the final structure, valuation and financial performance of the separated entity.

What Are the Risks for Apollo Hospitals Investors?

Despite its strong quarterly performance and expansion opportunities, Apollo Hospitals faces several challenges that investors should consider.

  • Profitability of new hospitals: Apollo's expansion plans involve significant upfront investments. With new hospitals already reporting operating losses, slower occupancy growth could increase the time required for these facilities to become profitable.
  • Pressure on hospital margins: A rise in staffing costs, medical expenses and other operating costs could affect profitability. Macquarie has also highlighted potential regulatory restrictions on margins for certain medical products as a risk.
  • HealthCo profitability: Although Apollo 24/7 has reached cash operating profitability, continued spending on technology and customer acquisition could limit future margin improvement.
  • Market expectations: Following the recent rally, investors may already be pricing in stronger future earnings. If hospital expansion or profitability improves more slowly than expected, the stock could face pressure even if the underlying business continues growing.

Author's Take

Apollo Hospitals' rally reflects more than a brokerage upgrade. Its Q2 FY27 results show that the company is treating more patients, generating higher revenue per patient and improving profitability across its businesses.

However, the most interesting part of Apollo's story is the difference between its existing hospitals and its new facilities. While established hospitals are supporting earnings growth, newer hospitals are still making operating losses.

This creates both an opportunity and a challenge. If Apollo can fill its new hospitals quickly while maintaining profitability at existing facilities, its expansion programme could support future earnings growth.

The improving performance of HealthCo and the proposed separation of the pharmacy business provide additional opportunities.

For investors, the key factor to monitor is how quickly Apollo converts its planned hospital expansion into profitable operations. The recent rally suggests improving market confidence, but sustaining that confidence will depend on occupancy growth, hospital margins and the profitability of new facilities.

Share: